Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Huadong Medicine Acquires Rights to Four Ashvattha Candidates for $45 Million

publication date: Apr 27, 2022

Huadong Medicine of Hangzhou entered a $45 million deal for China rights to four novel hydroxyl dendrimer candidates developed by Ashvattha Therapeutics of Redwood City, CA. The $45 million was part of Ashvattha’s $69 million Series B financing, which was announced at the same time. Ashvattha said HDTs have been shown to selectively target reactive inflammatory cells in diseased tissue, with the ability to cross the blood-brain barrier for neurology, ophthalmology and inflammatory disease indications. Huadong, founded in 1993, in-licenses products to diversify its portfolio of China drugs. More details....

Stock Symbol: (SHZ: 0963)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio Event
Singapore and Digital
April 26-27, 2023
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China